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A new subtype of frontotemporal lobar degeneration with FUS
pathology
Abstract
Frontotemporal dementia (FTD) is a clinical syndrome with a heterogeneous molecular basis. The
neuropathology associated with most FTD is characterized by abnormal cellular aggregates of either
transactive response DNA-binding protein with Mr 43 kDa (TDP-43) or tau protein. However, we
recently described a subgroup of FTD patients, representing around 10%, with an unusual clinical
phenotype and pathology characterized by frontotemporal lobar degeneration with neuronal inclusions
composed of an unidentified ubiquitinated protein (atypical FTLD-U; aFTLD-U). All cases were
sporadic and had early-onset FTD with severe progressive behavioural and personality changes in the
absence of aphasia or significant motor features. Mutations in the fused in sarcoma (FUS) gene have
recently been identified as a cause of familial amyotrophic lateral sclerosis, with these cases reported to
have abnormal cellular accumulations of FUS protein. Because of the recognized clinical, genetic and
pathological overlap between FTD and amyotrophic lateral sclerosis, we investigated whether FUS
might also be the pathological protein in aFTLD-U. In all our aFTLD-U cases (n = 15), FUS
immunohistochemistry labelled all the neuronal inclusions and also demonstrated previously
unrecognized glial pathology. Immunoblot analysis of protein extracted from post-mortem aFTLD-U
brain tissue demonstrated increased levels of insoluble FUS. No mutations in the FUS gene were
identified in any of our patients. These findings suggest that FUS is the pathological protein in a
significant subgroup of sporadic FTD and reinforce the concept that FTD and amyotrophic lateral
sclerosis are closely related conditions.
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Frontotemporal dementia (FTD) is a clinical syndrome with a heterogeneous molecular basis. The neuropathology associated
with most FTD is characterized by abnormal cellular aggregates of either transactive response DNA-binding protein with Mr
43 kDa (TDP-43) or tau protein. However, we recently described a subgroup of FTD patients, representing around 10%, with an
unusual clinical phenotype and pathology characterized by frontotemporal lobar degeneration with neuronal inclusions
composed of an unidentified ubiquitinated protein (atypical FTLD-U; aFTLD-U). All cases were sporadic and had early-onset
FTD with severe progressive behavioural and personality changes in the absence of aphasia or significant motor features.
Mutations in the fused in sarcoma (FUS) gene have recently been identified as a cause of familial amyotrophic lateral sclerosis,
with these cases reported to have abnormal cellular accumulations of FUS protein. Because of the recognized clinical, genetic
and pathological overlap between FTD and amyotrophic lateral sclerosis, we investigated whether FUS might also be the
pathological protein in aFTLD-U. In all our aFTLD-U cases (n = 15), FUS immunohistochemistry labelled all the neuronal
inclusions and also demonstrated previously unrecognized glial pathology. Immunoblot analysis of protein extracted from
post-mortem aFTLD-U brain tissue demonstrated increased levels of insoluble FUS. No mutations in the FUS gene were
identified in any of our patients. These findings suggest that FUS is the pathological protein in a significant subgroup of
sporadic FTD and reinforce the concept that FTD and amyotrophic lateral sclerosis are closely related conditions.
Keywords: frontotemporal lobar degeneration; frontotemporal dementia; FUS; fused in sarcoma; TLS; translocated in liposarcoma
Abbreviations: aFTLD-U = atypical frontotemporal lobar degeneration with neuronal inclusions composed of an unidentified
ubiquitinated protein; ALS = amyotrophic lateral sclerosis; FALS = familial amyptrophic lateral sclerosis; FTD = frontotemporal
dementia; FTLD = frontotemporal lobar degeneration; FUS = fused in sarcoma; IHC = immunohistochemistry; p62 = ubiquitin
proteasome system associated sequestosome p62; SALS = sporadic amyotrophic lateral sclerosis; SDS = sodium dodecyl sulphate;
TDP-43 = transactive response DNA-binding protein with Mr 43 kDa.
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Introduction
Frontotemporal dementia (FTD) is a clinical syndrome character-
ized by progressive changes in behaviour, personality and/or
language with relative preservation of memory (Neary et al.,
1998; McKhann et al., 2001). The neuropathology associated
with clinical FTD is heterogeneous, with the common feature
being relatively selective degeneration of the frontal and temporal
lobes (frontotemporal lobar degeneration, FTLD) (Trojanowski
and Dickson, 2001; Cairns et al., 2007a). As with many other
neurodegenerative conditions, the pathology in most cases of
FTLD also includes the presence of abnormal intracellular protein
aggregates. This feature is the basis of recently published consen-
sus recommendations for the nomenclature of FTLD in which
classification is based on the molecular defect that is presumed
to be pathogenic or most characteristic (Mackenzie et al., 2009).
Approximately half of cases show accumulation of hyper-
phosphorylated tau protein in neurons and glia (FTLD-tau). The
majority of tau-negative cases have neuronal inclusions that
were originally identified by their immunoreactivity for ubiquitin
(FTLD-U) (Jackson et al., 1996; Josephs et al., 2004; Johnson
et al., 2005; Mackenzie et al., 2006). Recently, the transactive
response (TAR) DNA-binding protein with Mr 43 kDa (TDP-43)
was identified as the pathological protein in both FTLD-U
(now referred to as FTLD-TDP) and amyotrophic lateral sclerosis
(ALS) (Arai et al., 2006; Neumann et al., 2006). This finding has
provided strong evidence that FTD with FTLD-TDP pathology, ALS
with dementia and classical ALS are all part of a clinicopathological
spectrum of disease.
Although TDP-43 was initially thought to be the pathological
protein in all cases of FTLD-U and ALS (Arai et al., 2006;
Neumann et al., 2006; Davidson et al., 2007), subsequent studies
identified some important exceptions (Cairns et al., 2007b; Holm
et al., 2007; Mackenzie et al., 2007; Josephs et al., 2008;
Pikkarainen et al., 2008). In two recent papers, we described a
subgroup of patients with sporadic FTD and FTLD-U pathology
that was negative for TDP-43, accounting for 10%–20% of our
respective FTLD-U series (Mackenzie et al., 2008a; Roeber et al.,
2008). The unusual and highly consistent clinical and pathological
phenotype suggested to us that these cases represent a specific dis-
ease entity, which we referred to as ‘atypical’ FTLD-U (aFTLD-U).
Identification of this group indicated that there was at least one
additional FTD-related protein yet to be discovered.
Recently, two studies identified mutations in the gene encoding
the fused in sarcoma (FUS) protein (also known as translated in
liposarcoma, TLS), as the cause of familial ALS (FALS) type 6
(Kwiatkowski et al., 2009; Vance et al., 2009). These studies
reported that a total of 14 different mutations were found in
26 unrelated families (4% of FALS in these combined series).
Most were missense mutations, affecting highly conserved regions
in exon 15 that encodes the C-terminus. With the exception of
one family with autosomal recessive disease, caused by the
c.1551C4G mutation (Kwiatkowski et al., 2009), all other
mutations produced autosomal dominant ALS, although with
incomplete penetrance. No mutations were found in 293 sporadic
ALS (SALS) cases screened in one study (Kwiatkowski et al., 2009).
The clinical phenotype was classical ALS, with a mean age of onset
of 46 years and mean disease duration of 33 months. There was no
associated cognitive dysfunction. Post-mortem pathology was
described in four patients and included degeneration of both
upper and lower motor neurons. One study reported only
increased neuronal cytoplasmic FUS-immunoreactivity in a single
affected individual (Kwiatkowski et al., 2009), while the other
described FUS-ir dystrophic neurites (DN) and globular neuronal
cytoplasmic inclusions (NCI) in lower motor neurons, in the
absence of TDP-43 pathology (Vance et al., 2009). In vitro experi-
ments from both groups suggested increased cytoplasmic FUS
localization in cells expressing mutations and one study reported
increased levels of insoluble FUS (Kwiatkowski et al., 2009).
The FUS gene, located on chromosome 16, consists of 15 exons
that encode a 526 amino-acid protein (Aman et al., 1996). The
C-terminus region contains multiple domains involved in
RNA–protein interactions, while the N-terminus functions in tran-
scriptional activation (Prasad et al., 1994). FUS is a ubiquitously
expressed protein (Aman et al., 1996; Andersson et al., 2008) that
binds to RNA (Crozat et al., 1993; Zinszner et al., 1997) and DNA
(Perrotti et al., 1998) and is involved in diverse cellular processes
including cell proliferation (Bertrand et al., 1999), DNA repair
(Baechtold et al., 1999), transcription regulation, RNA splicing
(Yang et al., 1998) and the transport of RNA between intracellular
compartments (Zinszner et al., 1997). In most cell types, FUS is
present in both the nucleus and cytoplasm, however in neurons
there is proportionally more in the nucleus and expression in glia is
exclusively nuclear (Andersson et al., 2008). FUS may be involved
in neuronal plasticity and maintenance of dendritic integrity by
transporting mRNA, including those that encode actin-related
proteins, to dendritic spines for local translation in response to
synaptic stimulation (Fujii et al., 2005a, b). In contrast, FUS defi-
cient neurons show decreased spine arborization and morphology
(Fujii et al., 2005a). Chromosomal translocation of the 50 portion
of FUS results in several fusion oncogenes that are each associated
with specific types of human cancer, including myxoid liposar-
coma, Ewing’s sarcoma and acute myeloid leukemia (Law et al.,
2006). FUS knock-out mice show perinatal mortality (Hicks et al.,
2000). The finding that FUS mutations cause FALS is the first
association between this protein and a neurodegenerative
condition.
The recognized clinical, genetic and pathological overlap
between ALS and FTD, and the high degree of functional
homology between FUS and another ALS/FTD-related protein
(TDP-43) (Lagier-Tourenne and Cleveland, 2009), led us to specu-
late that FUS might also be the pathological protein in some cases
of tau/TDP-43-negative FTLD. In this study, we investigate the
possible role of FUS in our aFTLD-U cases.
Materials and methods
Cases
All of the 15 cases of aFTLD-U from our previous two studies
(Mackenzie et al., 2008a; Roeber et al., 2008) were evaluated for
FUS pathology. These cases had previously been characterized as
having pathological inclusions that were immunoreactive for ubiquitin
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and the ubiquitin proteasome system associated sequestosome p62
(p62) but not for tau, TDP-43, neuronal intermediate filaments or
-synuclein. Neurological control cases included FTLD-TDP [n=12;
including two each of sporadic type 1, sporadic type 2, sporadic
type 3, familial with granulin gene (GRN) mutations, familial with
valosin-containing protein (VCP) mutations and familial linked to
chromosome 9p] (Cairns et al., 2007b); FTLD-tau [n= 8; including
two each of Pick’s Disease (PiD), progressive supranuclear palsy
(PSP), corticobasal degeneration (CBD) and argyrophilic grain disease
(AGD)]; Alzheimer’s disease (AD; n= 2); Parkinson’s disease combined
with dementia with Lewy bodies (n= 2); multiple system atrophy
(MSA; n= 2), Huntington’s disease (HD; n= 2) and ALS (n= 6; includ-
ing two each of SALS, FALS with superoxide dismutase (SOD)1 muta-
tions and FALS with SOD1 mutations excluded). Normal control tissue
was from two elderly patients with no history of neurological disease.
FUS antibodies
We tested a number of commercially available anti-FUS antibodies,
each of which recognizes a different epitope. Results are summarized
in Table 1. Immunohistochemistry (IHC) using three of the four anti-
bodies demonstrated the normal physiological pattern of staining and
also labelled the pathological lesions. One of these (Santa Cruz
sc-47 711) only worked on frozen sections. The other two showed
similar results on sections of formalin fixed, paraffin embedded mate-
rial. The polyclonal antibody from Sigma-Aldrich was used for all sub-
sequent IHC.
Immunohistochemistry
Cases of aFTLD-U had previously been immunostained with antibodies
against ubiquitin, p62, TDP-43, hyperphosphorylated tau, -synuclein,
Ab, -internexin, non-phosphorylated neurofilament (NF), phosphory-
lated neurofilament (pNF) and expanded polyglutamine repeat
regions, as described (Mackenzie et al., 2008a; Roeber et al., 2008).
In these cases, FUS IHC was performed on sections of frontal and
temporal neocortex, hippocampus, basal ganglia, midbrain and either
medulla or spinal cord. Ubiquitin, p62 and TDP-43 IHC was repeated
on selected sections. For control cases, the region of maximal
pathology was evaluated with FUS IHC.
All IHC was performed on 5 mm thick sections of formalin fixed,
paraffin embedded tissue using the Ventana BenchMark XT
automated staining system (Ventana, Tuscon, AZ) and developed
with aminoethylcarbizole (AEC). The primary antibodies employed
recognized FUS (Sigma-Aldrich anti-FUS; 1:25–1:200 with initial over-
night incubation at room temperature, following microwave antigen
retrieval), ubiquitin (DAKO anti-ubiquitin; 1:500, following microwave
antigen retrieval), p62 (BD Transduction Laboratories p62 Lck ligand;
1:500 following microwave antigen retrieval) and TDP-43 (ProteinTech
Group anti-TARDBP; 1:1000 following microwave antigen retrieval).
Based on the amount of normal physiological staining, it was apparent
that the anti-FUS sensitivity was greatly influenced by the degree of
tissue fixation and that this was only partially reversed by antigen
retrieval. Therefore, the dilution of the primary antibody was adjusted
in each case (from 1:25 to 1:200) to allow for faint physiological
staining that ensured sensitivity (internal positive control) but did
not compromise visualization of the pathology.
Immunofluorescence
Double-label immunofluorescence was performed on selected cases of
aFTLD-U and FTLD-TDP, using a mouse monoclonal anti-ubiquitin
antibody (Chemicon 1510; 1:20 000) and a rabbit polyclonal
(RP) anti-FUS antibody (Sigma-Aldrich anti-FUS; 1:25). The secondary
antibodies were Alexa Fluor 594 conjugated anti-rabbit and
Alexa Fluor 488 conjugated anti-mouse (Molecular Probes; 1:500).
40-6-diamidino-2-phenylindol (DAPI) was used for nuclear
counterstaining.
Biochemical fractionation and
immunoblot analysis
Fresh-frozen post-mortem frontal cortical tissue from aFTLD-U (n= 6),
FTLD-TDP (n= 6) and normal controls (n= 7) was used for the sequen-
tial extraction of proteins with buffers of increasing stringency using
a protocol commonly used for the sequential extraction of tau
(Zhukareva et al., 2002). Briefly, grey matter was extracted at
2 ml/g (v/w) by repeated homogenization and centrifugation steps
(120 000 g, 30 min, 4C) with high-salt (HS) buffer (50 mM
Tris–HCl, 750 mM NaCl, 10 mM NaF, 5 mM EDTA, pH 7.4),
1% Triton-X 100 (TX) in high-salt buffer, radioimmunoprecipitation
assay (RIPA) buffer [50 mM Tris–HCl, 150 mM NaCl, 5 mM EDTA,
1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate
(SDS)] and 2% SDS buffer. To prevent carry over, each extraction step
was performed twice. Only supernatants from the first extraction steps
were analysed while supernatants from the second wash steps were
discarded. The 2%-SDS insoluble pellet was extracted in 70% formic
acid (FA) at 0.5 ml/g (v/w). Formic acid was evaporated in a SpeedVac
system and the dried pellet was resuspendend in sample buffer and
the pH was adjusted to neutral with NaOH. Protease inhibitors were
added to all buffers prior to use. For immunoblot analysis, equal
volumes of fractions from different samples (10 ml of high-salt
buffer and TX, 20ml of RIPA and SDS, 25 ml of formic acid) were
resolved by 7.5% SDS–polyacrylamide gel electrophoresis (SDS–
Table 1 Anti-FUS antibodies tested
Company Product no. Type Epitope (aa 1–526) Paraffin section
IHC (dilution)
Frozen section
IHC (dilution)
Immunoblot
Bethyl Laboratories A300-302A RP N-terminus (aa 1–50) Yes Yes Yes
(1:200–500) (1:5000–10 000) (1:20 000)
Sigma-Aldrich HPA008784 RP mid region (aa 86–213) Yes Not tested Yes
(1:25–500) (1:500)
Bethyl Laboratories A300-292A RP mid region (aa 200–250) No No Yes
(1:2500)
Santa Cruz Biotechnology sc-47711 MM C-terminus No Yes Yes
(1:50–200) (1:1000)
MM = mouse monoclonal; RP = rabbit polyclonal.
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PAGE) and transferred to polyvinylidene difluoride membranes
(Millipore, Billerica, MA). Following transfer, membranes were blocked
with Tris buffered saline (TBS) containing 5% powdered milk and
probed with anti-FUS antibodies (see Table 1 for dilutions). Primary
antibodies were detected with horseradish peroxidase (HRP)-conju-
gated anti-rabbit or anti-mouse IgG (Jackson ImmunoResearch
Europe, UK) and signals were visualized by an HRP-based chemilumin-
escent reaction (Pierce, Rockford, IL) and the Chemiluminescence
Imager Stella 3200 (Raytest, Switzerland). The intensity of the FUS
bands in the soluble (HS and TX) and insoluble (SDS) fractions were
measured and the ratio calculated.
Molecular genetic analysis
Molecular genetic analysis was performed on six cases of aFTLD-U and
six pathologically normal controls where fresh-frozen post-mortem
cerebellar tissue was available.
Genomic DNA sequencing
Genomic DNA (gDNA), prepared using standard automation protocols
with the AutoGenprep 245T (Autogen, Holliston, MA), was used as
a template to amplify the 15 exons of FUS by polymerase chain reac-
tion (PCR). Primers designed to flanking intronic regions were used for
both PCR and sequencing reactions (primer sequences available on
request). Twenty microlitres of PCR product for each exon (Qiagen,
Valencia, CA) was purified using the Ampure system (Agencourt
Bioscience Corporation, Beverly, MA), then sequenced in both
directions using Big Dye chemistry (Applied Biosystems, Foster City,
CA). Sequencing products were purified using the CleanSeq method
(Agencourt Bioscience Corporation, Beverly, MA) and analysed on an
ABI3700.
Complementary DNA analysis
Total RNA was extracted using Trizol and the Pure Link system
(Invitrogen, Carlsbad, CA), and the quality and quantity assessed on
the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). First-
strand synthesis was carried out using the Superscript III system
(Invitrogen, Carlsbad, CA), with 200 ng of total RNA as the template
and a gene-specific primer, designed to the 30 untranslated region
(UTR) of FUS (CTTGGGTGATCAGGAATTG). The resultant comple-
mentary DNA (cDNA) was diluted 1:5 and used as the template for
RT–PCR reactions (Qiagen, Valencia, CA) using the following primer
pairs:
c.1F:CATGGCCTCAAACGATTATAC and c.6:ATGGAGGATTGATC
TTGGC,
c.5F:GCAGAACCAGTACAACAGC and c.10R:CTTCAGCTTGCCAG
TTTC,
c.9F:CAATTGAGTCTGTGGCTGATTAC and c.14R:CACCACGACGA
TCATCCC
and c.12F:GTCCTAATCCCACCTGTGAG and c.utrR:CTTGGGTGAT
CAGGAATTG.
RT–PCR reactions were denatured for 3 min at 94C, then cycled
at 60–50C touchdown (3000, 3000, 4500) for 35 cycles. RT–PCR
products were visualized by electrophoresis on 2% agarose gel and
sequenced in both directions.
mRNA expression analysis
Total RNA samples were normalized to 50 ng/ml and using 200 ng as
the template, a reverse transcription reaction was performed using
a 1:1 mix of random hexamers and oligo(dT) primers, and the
SuperScript III system (Invitrogen, Carlsbad, CA). Gene expression
assays were ordered from Applied Biosystems for FUS
(Hs00192029_m1), and for the endogenous controls GAPDH
(Hs00266705_g1), YWHAZ (Hs00852925_sH) and HPRT1
(Hs99999909_m1). Real-time PCR was performed on an ABI 7900
using the TaqMan method. Reactions contained 1 ml of cDNA ampli-
fied with 0.25 ml primer/probe mix and 2.5 ml TaqMan 2Universal
PCR Master Mix (Applied Biosystems, Foster City, CA). The cycling
parameters recommended by the manufacturer were followed; 50C
for 2 min, 95C for 10 min, followed by 40 cycles of 95C for
15 s/60C for 1 min. All samples were run in triplicate and normalized
to GAPDH (or other controls where necessary). The carboxyfluorescein
(FAM)-fluorescent signal was analysed using SDS2.2.2 software, and
relative quantities of FUS mRNA were determined using the ct
method.
Results
Clinical summary
A detailed clinical description of these cases has been published
previously (Mackenzie et al., 2008a; Roeber et al., 2008). In brief,
the 15 subjects included nine females and six males. The mean
age of disease onset was 38 years (range 28–55 years) and the
mean duration was 7 years (range 4–15 years). All fulfilled clinical
criteria for FTD and presented with severe progressive changes in
personality and behaviour. Common features included lack of
insight, poor judgement, decline in personal hygiene, hyperorality,
poor attention, emotional blunting, disinhibition with inappropriate
interpersonal conduct and antisocial behaviour that was sometimes
aggressive and even criminal. Language remained fluent but even-
tually showed features of frontal dysfunction with reduced output,
aspontaneity, stereotypy, perseveration and eventual mutism.
Memory was only affected late in the disease course. Mild
Parkinsonism was present in some but none showed clinical
evidence of pyramidal system dysfunction. None of the subjects
had a family history of similar disease.
Neuropathology
General findings
All cases showed symmetric atrophy of the frontal and temporal
lobes and caudate nucleus. Histological evidence of chronic
degeneration was present in the frontal and temporal neocortex,
hippocampal CA1 sector and subiculum (hippocampal sclerosis),
striatum, globus pallidus and substantia nigra. As previously
described, no pathological changes were demonstrated with
silver impregnation methods (Bielschowsky or Gallyas stains) or
IHC for Ab, tau, -synuclein, neurofilament proteins, -internexin,
TDP-43 or expanded polyglutamine repeats (Mackenzie et al.,
2008a, Roeber et al., 2008).
Ubiquitin/p62 IHC
All cases showed similar morphology and anatomical distribution
of pathology. Variable numbers of well-defined, round, oval or
crescentic neuronal cytoplasmic inclusions (NCI) were present in
middle and deeper layers of neocortex, along with occasional short
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dystrophic neurites. Similar NCI were moderate to numerous in the
dentate granule cells and less abundant in hippocampal pyramidal
neurons and subcortical regions including the striatum, nucleus
basalis, hypothalamus, substantia nigra and periaqueductal
grey matter. Despite there being no obvious neuronal loss or
degenerative changes, ub-ir inclusions were present in lower
motor neurons (LMN) of the hypoglossal nucleus and/or spinal
cord in 7 of the 12 (58%) cases available for evaluation.
In addition to cytoplasmic inclusions, ubiquitin IHC demon-
strated a unique type of neuronal intranuclear inclusion (NII) in
all cases. These appeared as a single straight, curved or twisted
(vermiform), thick filament. Neuronal intranuclear inclusions were
most numerous in the dentate granules cells but also found in
pyramidal neurons of the neocortex and hippocampus and some
subcortical regions. Unlike the neuronal cytoplasmic inclusions and
dystrophic neurites, neuronal intranuclear inclusions were only
immunoreactive for ubiquitin and not p62.
FUS IHC/immunofluorescence
The normal physiological staining pattern of FUS was equally well
demonstrated in normal controls, neurological controls and
aFTLD-U cases. This consisted of strong immunoreactivity of
neuronal nuclei, weaker but consistent staining of neuronal
cytoplasm and more variable reactivity of glial nuclei (Fig. 1A)
(Andersson et al., 2008). In both the nuclei and cytoplasm, the
normal staining pattern was generally diffuse but with occasional
small granules.
In cases of aFTLD-U, FUS IHC labelled neuronal cytoplasmic
inclusions, neuronal intranuclear inclusions and dystrophic neurites
of similar morphology, number and anatomical distribution
as were demonstrated with ubiquitin and p62 antibodies
(Fig. 1B–H). Some types of inclusions were even more apparent
with FUS IHC. For instance, all cases in which medulla or spinal
cord tissue was available had at least some large globular FUS-ir
neuronal cytoplasmic inclusion in LMN (Fig. 1H, Table 2),
compared to only 58% of cases with ub-ir NCI in this location
(see above). FUS IHC also demonstrated moderate numbers of
oval or flame-shaped glial cytoplasmic inclusions in the white
matter that were not evident with ubiquitin IHC (Fig. 1I). On
average, the burden of FUS pathology tended to be greatest in
the hippocampal dentate fascia, moderate in the frontal and
temporal neocortex and striatum, while other subcortical regions
were less consistently involved and to a milder degree (Table 2).
The co-localization of FUS and ubiquitin in NCI and NII was
confirmed with double label immunofluorescence (Fig. 2).
The pathological changes were immunoreactive with different
Figure 1 FUS IHC performed on sections of post-mortem brain tissue from normal control (A) and aFTLD-U subjects (B–I). The normal
physiological staining pattern, consisting of strong immunoreactivity of neuronal nuclei, weaker but consistent staining of neuronal
cytoplasm and more variable reactivity of glial nuclei was demonstrated in all cases, including normal controls (A), neurological controls
and aFTLD-U subjects (B). In patients with aFTLD-U, neurons with inclusions (arrow) retained at least some of the normal nuclear and
cytoplasmic staining (B). Neuronal cytoplasmic inclusions (NCI) were most numerous in the middle and deeper layers of neocortex
(C–E) and dentate granule cells of the hippocampus (F) and ranged in morphology from round or oval (D and F) to crescentic (E).
Dentate granule cells with vermiform neuronal intranuclear inclusions (arrows) often also had NCI (G). Globular NCI were present in
lower motor neurons (H). Flame-shaped glial cytoplasmic inclusions were present in white matter (I). FUS IHC with concentration of
primary antibody adjusted to demonstrate normal physiological staining (A and B) or optimize visualization of pathological inclusions
(C–I). Scale bar: A and H, 20 mm; B, E, G and I, 10 mm; C, 50mm; D, 15 mm; F, 30 mm.
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FUS antibodies that recognize the N-terminus, mid-region and C-
terminus of the protein, respectively (Table 1). Although the vari-
ation in staining intensity prevented quantitation, it was evident
that neurons harbouring inclusions (either NCI or NII) still retained
at least some of the normal distribution of nuclear and cytoplasmic
staining (Figs 1B and 2).
With one exception, none of the normal or neurological controls
showed any FUS-ir pathology. Specifically, FUS IHC did not label
senile plaques, neurofibrillary tangles, dystrophic neurites, Lewy
bodies, Lewy neurites, Pick bodies, ballooned neurons, neuronal
inclusions in ALS or FTLD with TDP pathology (Fig. 2) or glial
inclusions in tauopathies or MSA. The exception was
Huntingdon’s disease in which the characteristic NII were strongly
FUS-ir, a finding that has been reported previously (Doi et al., 2008).
FUS immunoblot analysis
To characterize FUS biochemically, protein was sequentially
extracted from fresh-frozen post-mortem brain tissue from
aFTLD-U, FTLD-TDP and controls, using buffers containing
increasingly strong detergents or acids. Fractions were then sepa-
rated by SDS–PAGE and analysed by anti-FUS immunoblotting.
Figure 2 Double-label immunofluorescence of inclusions in aFTLD-U and FTLD-TDP. Neuronal cytoplasmic inclusions (A) and neuronal
intranuclear inclusions (B and C) in aFTLD-U cases showed colocalization of ubiquitin (green) and FUS (red). Note the presence of
a cytoplasmic and intranuclear inclusion (arrow) in a single cell (C). No obvious difference in the intensity of FUS nuclear staining was
observed between neurons with and without inclusions (A). In sharp contrast, ubiquitin-positive inclusions in FTLD-TDP were not
stained with anti-FUS antibodies (D). Scale bar: A and D, 50 mm; B, 20 mm; C, 16.5mm.
Table 2 Anatomical distribution and severity of FUS-immunoreactive pathology in aFTLD-U cases
Case
1
Case
2
Case
3
Case
4
Case
5
Case
6
Case
7
Case
8
Case
9
Case
10
Case
11
Case
12
Case
13
Case
14
Case
15
Frontotemporal
neocortex
++ ++ ++ ++ ++ +++ + + ++ + +++ + + ++ +
Hippocampus +++ NA ++ ++ +++ +++ ++ + ++ ++ +++ ++ +++ ++ +++
Striatum ++ ++ + ++ ++ ++ + + ++ + ++ NA + NA ++
Lower motor
neurons
+ ++ ++ NA ++ + + NA NA + + NA ++ + NA
Grading: = absent; += mild; ++ = moderate; +++ = severe; NA = not available.
Score is aggregate of all FUS-positive pathology, including neuronal cytoplasmic inclusions, neuronal intranuclear inclusions, glial inclusions and dystrophic neurites.
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FUS was consistently detected as a major 73-kDa band in the
soluble high salt fraction from aFTLD-U as well as from normal or
neurological controls (Fig. 3). Some cases, independent of the
diagnosis, also showed a weak band in the soluble TX fraction.
Although the amount of FUS in the SDS fraction, which is
enriched for more insoluble proteins, varied within each group
of patients, aFTLD-U cases tended to show stronger bands
compared to both normal and FTLD-TDP controls. Within the
aFTLD-U group, the amount of this insoluble FUS species roughly
correlated with the severity of FUS pathology as detected by IHC
(Table 2). The shift of FUS towards the insoluble fraction in
aFTLD-U was confirmed by quantitative analysis of the intensity
of the FUS bands in the soluble (HS and TX) and insoluble (SDS)
fractions and calculation of insoluble:soluble ratios (Fig. 4). While
there was some overlap between the aFTLD-U and control groups,
statistical analysis revealed significantly higher ratios for aFTLD-U
(mean = 0.62 0.25) compared to FTLD-TDP (mean = 0.17 0.19)
or controls (mean = 0.21 0.22) (P50.05; Student’s t-test).
Despite the shift of FUS to the insoluble fraction in aFTLD-U,
we found no other evidence of biochemical abnormality; specifi-
cally, immunoblot analysis using four antibodies that each recog-
nize different epitopes across the entire FUS protein (Table 1) did
not identify any additional protein bands of higher or lower
molecular weight.
Molecular genetic analysis of FUS
Sequencing of all exons and flanking intronic regions of FUS
gDNA did not identify any mutations in the six aFTLD-U cases
Figure 3 Biochemical analysis of FUS. Proteins were sequentially extracted from aFTLD-U, FTLD-TDP and control (CO) brains.
High salt (lane 1), Triton X-100 (lane 2), RIPA (lane 3), 2% SDS (lane 4) and formic acid (lane 5) fractions were separated by 7.5%
SDS–PAGE and immunoblotted with anti-FUS antibody (RP A300-302A). All cases showed a strong 73-kDa band in the soluble
high-salt fraction (lane 1). Although the amount of SDS–soluble FUS (lane 4) was variable within each group, aFTLD-U cases always
showed a strong band that was greater than that seen for most of the controls.
Figure 4 Ratio of insoluble to soluble FUS. Band intensities of
FUS in insoluble (SDS fraction) and soluble (high salt and
Triton-X100 fractions) were analysed and the ratio calculated.
Ratios are depicted as a box and whiskers blot that shows the
range of values, with the box being subdivided into the 25 and
75% quartiles by the median; circles represent outliers, filled
rhombus represent the mean. Although there is some overlap,
the aFTLD-U group showed significantly higher ratios
compared to both the FTLD-TDP and control groups (P50.05).
2928 | Brain 2009: 132; 2922–2931 M. Neumann et al.
analysed. In addition, complete FUS cDNA analyses, using four
overlapping fragments, did not show aberrant transcripts by
agarose gel-electrophoresis. cDNA sequencing further excluded
mutations but confirmed the known alternative splicing at the
start of exon 4, resulting in two transcripts with a 3-bp difference
(Morohoshi et al., 1998). Finally, FUS mRNA expression in the
aFTLD-U cases did not show any significant increase or decrease
in expression, compared to normal controls.
Discussion
The findings of our study provide strong support for FUS being
the pathological protein in an important new subtype of FTD.
We found that FUS co-localized with all the ub-ir pathological
inclusions in our aFTLD-U cases, including dystrophic neurites,
neuronal cytoplasmic inclusions and, perhaps most importantly,
the unusual vermiform NII that is the most unique feature of
these cases. Moreover, FUS immunohistochemistry demonstrated
additional inclusions, in glial cells, that were not seen with
ubiquitin staining. The pathology was demonstrated with multiple
antibodies that recognize different epitopes of the FUS protein
but not with antibodies against the other proteins commonly
associated with neurodegenerative disease (tau, -synuclein,
TDP-43 and intermediate filament proteins). FUS immunoreactivity
was specific for this group of cases and did not label the charac-
teristic pathological lesions of FTLD-tau, FTLD-TDP, ALS or most
of the other neurodegenerative conditions we examined. Although
the only evidence we found for a disease-associated biochemical
modification of FUS in aFTLD-U was a relative change in solubility
(higher mean ratio of insoluble versus soluble FUS in aFTLD-U
compared with controls), this none-the-less suggests that FUS
accumulation is a primary rather than a secondary phenomenon
in this condition (i.e. normal FUS is not simply becoming
entrapped in pre-existing inclusions made of some other protein).
The recent recognition that FUS plays a pathogenic role in a
subgroup of ALS supports its potential to cause FTD, which is
considered to be a closely related neurodegenerative syndrome.
Finally, the highly unusual and stereotypic clinical phenotype of
our aFTLD-U subjects is consistent with these cases representing
a distinct entity, which should have a novel and consistent pathol-
ogy. In accordance with the recently proposed system of FTLD
nomenclature (Mackenzie et al., 2009), this newly recognized
pathology should be designated as FTLD-FUS.
It is perhaps not surprising to discover that FUS is also the
pathological protein in a subgroup of FTD, given the high
degree of functional homology it shares with another ALS/FTLD
related protein, TDP-43 (recently reviewed in Lagier-Tourenne
and Cleveland, 2009). Both TDP-43 and FUS are ubiquitously
expressed DNA/RNA-binding proteins involved in multiple aspects
of gene expression, transcription regulation, RNA splicing, trans-
port and translation (Crozat et al., 1993; Prasad et al., 1994;
Aman et al., 1996; Zinszner et al., 1997; Perrotti et al., 1998;
Yang et al., 1998; Andersson et al., 2008; Buratti et al., 2008).
Under normal circumstances, both proteins are predominantly
localized to the nucleus but shuttle between the nucleus and cyto-
sol (Andersson et al., 2008; Buratti et al., 2008). In fact, it was
this functional homology with TDP-43 that led researchers to
target FUS early in the process of screening candidate genes in
the linked region on chromosome 16 (Kwiatkowski et al., 2009;
Vance et al., 2009).
The similarities between FUS and TDP-43 extend to their role in
disease. To date, mutations in both genes have predominantly
been associated with autosomal dominant forms of classical ALS
(Mackenzie et al., 2008b; Kwiatkowski et al., 2009; Vance et al.,
2009). Most of the pathogenic mutations in both genes are mis-
sense changes, affecting highly conserved sites in the C-terminus.
As in ALS with TDP-43 pathology (Arai et al., 2006; Neumann
et al., 2006; Davidson et al., 2007), FUS mutations result in
abnormal redistribution of the protein from the nucleus to the
cytoplasm where it forms insoluble aggregates (Kwiatkowski
et al., 2009; Vance et al., 2009). Our findings further extended
these similarities by demonstrating that, in FTLD, both proteins
form a common range of pathological inclusion bodies, including
NCI, NII, DN and glial cytoplasmic inclusions. However, our results
also suggest there may be some important differences between
pathological forms of FUS and TDP-43. Cells with FUS-positive
inclusion bodies retained at least some of the normal nuclear
and cytoplasmic distribution of FUS staining, which is in contrast
to the dramatic reduction in nuclear staining for TDP-43 in cells
bearing TDP-43-positive inclusions (Neumann et al., 2006).
Immunoblot analysis of our aFTLD-U cases did not show convin-
cing evidence of abnormal processing of FUS and IHC suggested
the inclusions contain the full-length protein. These findings have
important implications regarding the pathogenic mechanism of
FUS-related neurodegeneration and require more detailed
investigation.
The concept that ALS and FTD with FTLD-U pathology are
closely related conditions was strongly supported by the identifi-
cation of TDP-43 as the pathological protein in both groups
(Arai et al., 2006; Neumann et al., 2006; Davidson et al., 2007)
and is now reinforced by the discovery that FUS plays a
pathogenic role in this same spectrum of disease. The consistent
involvement of LMN in our aFTLD-U cases, despite an absence of
clinical features of ALS, is further support of this overlap. Given
initial reports indicating that cases of ALS with FUS mutations
have only FUS pathology and no abnormal TDP-43
(Kwiatkowski et al., 2009; Vance et al., 2009); and the finding
that our neurological control cases of SALS had pathological
TDP-43 but not FUS, it appears that ALS can be caused by
abnormalities in these two highly similar but distinct molecular
pathways. Comparison of the IHC results of our FTLD-TDP
versus aFTLD-U cases, suggests the same dichotomous pathogen-
icity in FTD.
In summary, we provide evidence that FUS is the pathological
protein in a new subtype of FTD, with a unique clinical phenotype
and neuropathology (FTLD-FUS). The full spectrum of FTLD-FUS
remains to be defined and future studies are needed to examine
the possible role of FUS in other types of tau/TDP-43-negative
FTLD, including basophilic inclusion body disease, neuronal
intermediate filament inclusion disease, hereditary dementia with
leukodystrophy and spheroids and FTD-3 caused by CHMP2B
mutations. The absence of any identifiable FUS gene abnormality
in our aFTLD-U cases is perhaps not surprising given that all
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appeared to be sporadic. None-the-less, a recent report that muta-
tions in TARDBP may cause both FTD and ALS (Benajiba et al.,
2009) indicates that FUS should also be considered a candidate
gene in cases of familial FTD, particularly those with confirmed
FUS pathology.
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